High‐Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib‐Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition

James, Daniel; Green, Simone; Molica, Stefano; Allsup, David

Abstract

The coexistence of chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) in the same patient is exceedingly rare, with only a few cases reported in the literature. Here, we report a patient with CML who, having achieved a major molecular response with imatinib, subsequently developed CLL, which necessitated the concomitant administration of ibrutinib.

Citation

James, D., Green, S., Molica, S., & Allsup, D. (2024). High‐Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib‐Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition. Case Reports in Hematology, 2024, Article 1813512. https://doi.org/10.1155/2024/1813512

• Journal Article Type: Article
• Acceptance Date: Sep 2, 2024
• Online Publication Date: Nov 15, 2024
• Publication Date: Nov 15, 2024
• Deposit Date: Nov 18, 2024
• Publicly Available Date: Nov 18, 2024
• Journal: Case Reports in Hematology
• Print ISSN: 2090-6560
• Electronic ISSN: 2090-6579
• Publisher: Wiley
• Peer Reviewed: Peer Reviewed
• Volume: 2024
• Article Number: 1813512
• DOI: https://doi.org/10.1155/2024/1813512
• Keywords: Chronic lymphocytic leukemia; Chronic myeloid leukemia; Tyrosine kinase inhibitors
• Public URL: https://hull-repository.worktribe.com/output/4920110